Abstract
Report Details
What does the future hold for small-molecule cancer treatments? Visiongain's
report shows you potential revenues to 2021, discussing trends and
opportunities in that market.
Find revenue predictions at overall world market, product and national levels
to 2021. Through our research and analysis we aim to save you time and help in
your decisions.
Where are the 10 leading drugs heading? Find out how products such as
Glivec/Gleevec, Revlimid, Alimta, Taxotere, Velcade and Tarceva can perform to
2021. See potential revenues and other trends.
Discover prospects for Novartis, Celgene, Eli Lilly, Sanofi, Roche, Pfizer and
other companies. Many commercial opportunities in targeted cancer treatment
remain.
Which national markets will achieve the fastest revenue growth? Our report
shows you and explains. The targeted small-molecule cancer drug market will
expand this decade.
There is a strong R&D pipeline. You can review candidates for treating lung,
breast, colorectal, stomach and prostate cancers, as well as multiple myeloma.
Also, review immunomodulators, apoptosis inducers, epigenetic agents and other
technologies.
How will changes in the pharma industry affect small-molecule cancer
treatments? Our study discusses personalised medicine and other developments,
as well as competition. Find out how events this decade will affect the
industry and market for anti-cancer drugs.
Our report provides data, analysis and opinion to benefit your research,
calculations, meetings and presentations. You can receive answers now in our
work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In our report you find revenue forecasts, growth rates, market shares,
qualitative analyses (incl. SWOT and STEP), an R&D review and opinion from our
survey. You receive 109 tables and charts and two research interviews.
Advantages of Small-Molecule Targeted Cancer Therapies: World Market 2011-2021 for your work
Our report gives you the following advantages in particular:
- Find predicted revenues to 2021 for the targeted small-molecule cancer
drug market at world level, seeing revenue growth
- Discover revenue forecasts to 2021 for leading products, assessing market
potentials
- Receive revenue forecasts to 2021 for the US, Japan, Germany, France, the
UK, Spain, Italy, China and India
- Review R&D for treating a range of cancers, seeing pipeline trends in
oncology
- Investigate competition and opportunities influencing the industry and
market
- Find out what will stimulate and restrain the industry and market from 2011
- View opinion from our survey, receiving detailed interview transcripts.
There, you find a distinctive mix of quantitative and qualitative analyses
with independent predictions. We tackle many questions on cancer treatment,
helping you to stay ahead.
Gain industry and market analysis now for small-molecule anti-cancer drugs
Our report is for everybody needing industry and market analysis for
small-molecule targeted cancer treatments. Find trends and answers. Avoid
missing out - please order our report now.
Table of Contents
1. Executive Summary
- 1.1 Overview of Findings
- 1.2 Scope and Format of the Report
- 1.3 Research and Analysis Methods
2. Introduction: Cancer, its Physiology, Burden and Treatment
- 2.1 Targeted Cancer Therapies
- 2.2 The Physiology of Cancer
- 2.2.1 Uncontrolled Growth
- 2.2.2 Dedifferentiation
- 2.2.3 Invasiveness and Metastasis
- 2.2.4 Causes of Cancer
- 2.3 Incidence and Mortality for Cancer
- 2.3.1 Incidence
- 2.3.2 Mortality
- 2.3.3 Survival
- 2.3.3.1 The Developed World
- 2.3.3.2 The Developing World
- 2.4 Treating Tumours
- 2.4.1 Chemotherapy
- 2.4.2 Traditional Antineoplastics
- 2.4.3 Novel Antineoplastics
- 2.4.3.1 Kinase Receptor Antagonists
- 2.4.3.2 Other Novel Antineoplastics
- 2.4.4 Hormone Therapies
- 2.4.5 Active Immunotherapy
- 2.4.6 Passive Immunotherapy: Monoclonal Antibodies
- 2.5 Small-Molecule Targeted Cancer Therapies
- 2.5.1 Signal Transduction Inhibitors
- 2.5.2 Gene Expression and Other Cellular Function Regulators
- 2.5.3 Small-Molecule Apoptotic Inducing Drugs
- 2.5.4 Angiogenesis Blockers
- 2.6 Targeted Cancer Therapies: Small-Molecule Drugs
3. The Small-Molecule Cancer Therapies Market, 2011-2021
- 3.1 The World Small-Molecule Cancer Therapies Market in 2010
- 3.2 Growing Market for Small-Molecule Cancer Therapies
- 3.2.1 Sales Forecast for Small-Molecule Cancer Therapies, 2011-2015
- 3.2.2 Sales Forecast for Small-Molecule Cancer Therapies, 2016-2021
- 3.3 Leading Products in Small-Molecule Cancer Therapies Market
4. Small-Molecule Cancer Therapies: Leading National Markets, 2011-2021
- 4.1 The US Small-Molecule Cancer Therapies Market, 2011-2021
- 4.2 The Japanese Small-Molecule Cancer Therapies Market, 2011-2021
- 4.3 The Leading European Small-Molecule Cancer Therapies Markets, 2011-2021
- 4.4 Emerging-Economy Small-Molecule Cancer Therapies Markets
- 4.5 The Chinese Small-Molecule Cancer Therapies Market, 2011-2021
- 4.6 The Indian Small-Molecule Cancer Therapies Market, 2011-2021
- 4.7 Summary of Market Forecasts
5. Leading Small-Molecule Anti-Cancer Products, 2011-2021
- 5.1 Glivec/Gleevec (Novartis)
- 5.1.1 Glivec/Gleevec Sales 2010
- 5.1.2 Glivec/Gleevec Sales Forecast, 2011-2015
- 5.1.3 Glivec/Gleevec Sales Forecast, 2016-2021
- 5.1.4 Tasigna Set to Replace Glivec/Gleevec
- 5.2 Revlimid (Celgene)
- 5.2.1 Revlimid Sales 2010
- 5.2.2 Secondary Malignancies
- 5.2.3 Revlimid Sales Forecast, 2011-2015
- 5.2.4 Revlimid Sales Forecast, 2016-2021
- 5.3 Alimta (Eli Lilly)
- 5.3.1 Alimta Sales 2010
- 5.3.2 Patent Disputes
- 5.3.3 Alimta Sales Forecast, 2011-2015
- 5.3.4 Alimta Sales Forecast, 2016-2021
- 5.4 Taxotere (Sanofi)
- 5.4.1 Taxotere Sales 2010
- 5.4.2 Patent Expiry
- 5.4.3 Taxotere Sales Forecast, 2011-2015
- 5.4.4 Taxotere Sales Forecast, 2016-2021
- 5.5 Velcade (Takeda/J&J)
- 5.5.1 Velcade Sales 2010
- 5.5.2 Recent Developments
- 5.5.3 Velcade Sales Forecast, 2011-2015
- 5.5.4 Velcade Sales Forecast, 2016-2021
- 5.6 Arimidex (AstraZeneca)
- 5.6.1 Arimidex Sales 2010
- 5.6.2 Patent Expiry
- 5.6.3 Arimidex Sales Forecast, 2011-2015
- 5.6.4 Arimidex Sales Forecast, 2016-2021
- 5.7 Tarceva (Roche)
- 5.7.1 Tarceva Sales 2010
- 5.7.2 Patent Expiry
- 5.7.3 Tarceva Sales Forecast, 2011-2015
- 5.7.4 Tarceva Sales Forecast, 2016-2021
- 5.8 Sutent (Pfizer)
- 5.8.1 Sutent Sales 2010
- 5.8.2 Generic Launch Expected for Sutent
- 5.8.3 Sutent Sales Forecast, 2011-2015
- 5.8.4 Sutent Sales Forecast, 2016-2021
- 5.8.5 Additional Indication Approval.
- 5.8.6 Late-Stage Clinical Trials for Additional Uses and Dosage Forms
for Sutent
- 5.9 Nexavar (Bayer/Onyx)
- 5.9.1 Nexavar Sales 2010
- 5.9.2 Patent Expiry
- 5.9.3 Nexavar Sales Forecast, 2011-2015
- 5.9.4 Nexavar Sales Forecast, 2016-2021
- 5.10 Sprycel (Bristol-Myers Squibb)
- 5.10.1 Sprycel Sales 2010
- 5.10.2 Patent Expiry
- 5.10.3 Sprycel Sales Forecast, 2011-2015
- 5.10.4 Sprycel Sales Forecast, 2016-2021
6. R&D Pipeline for Small-Molecule Cancer Products
- 6.1 An Overview
- 6.2 Small-Molecule Lung Cancer Pipeline 2011
- 6.2.1 BIBW 2992 (Boehringer Ingelheim)
- 6.2.2 Crizotinib (Pfizer)
- 6.3 Small-Molecule Breast Cancer Pipeline 2011
- 6.3.1 Line Extensions
- 6.3.2 Halaven (Eisai)
- 6.4 Small-Molecule Colorectal Cancer Pipeline 2011
- 6.4.1 BAY 73-4506 (Bayer)
- 6.4.2 KRX 0401 (Keryx/Aeterna Zentaris)
- 6.5 Small-Molecule Stomach Cancer Pipeline 2011
- 6.5.1 Line Extensions
- 6.5.2 Telatinib (ACT Biotech)
- 6.6 Small-Molecule Prostate Cancer Pipeline 2011
- 6.6.1 MDV 3100 (Astellas/Medivation)
- 6.6.2 CB7630 (Centocor Ortho Biotech)
- 6.7. Small-Molecule Multiple Myeloma Pipeline, 2011
- 6.7.1 Proteasome Inhibitors: the Next Generation
- 6.7.1.1 CEP 18770 (Cephalon)
- 6.7.1.2 Marizomib (Nereus)
- 6.7.1.3 MLN 9708 (Takeda)
- 6.7.1.4 CEP 28331 (Cephalon)
- 6.7.2 Immunomodulators: the Past or the Future for Myeloma Treatment?
- 6.7.2.1 Afinitor (Novartis)
- 6.7.2.2 E-Selectin Antagonists (GlycoMimetics)
- 6.7.3 Histone Deacetylase Inhibitors: An Important New Sector
- 6.7.3.1 Istodax (Celgene Corporation)
- 6.7.3.2 Zolinza (Merck & Co.)
- 6.7.3.3 AR 42 (Arno)
- 6.7.3.4 Givinostat (Italfarmaco)
- 6.7.3.5 HDAC6 Inhibitors (Acetylon)
- 6.7.4 Kinase Inhibitors/Signal Transduction Blockers: The Largest
Pipeline Sector
- 6.7.4.1 Votrient (GlaxoSmithKline)
- 6.7.4.2 Lenocta (VioQuest)
- 6.7.4.3 Ruxolitnib (Novartis)
- 6.7.4.4 Lestaurtnib (Cephalon)
- 6.7.4.5 Masitnib (AB Science)
- 6.7.4.6 AT 9283 (Astex Therapeutics)
- 6.7.4.7 Dovitnib (Novartis)
- 6.7.4.8 P276 (Piramal Life Sciences)
- 6.7.4.9 PD332991 (Pfizer)
- 6.7.4.10 ENMD 2076 (EntreMed)
- 6.7.4.11 AT 7519 (Astex Therapeutics)
- 6.7.4.12 MLN 8237 (Takeda)
- 6.7.4.13 Estybon (Onconova)
- 6.7.4.14 CX 4945 (Cylene)
- 6.7.4.15 GDC 0941 (Roche)
- 6.7.4.16 INK 128 (Intellikine)
- 6.7.4.17 SF 1126 (Semafore)
- 6.7.4.18 SNS 032 (Sunesis/Bristol-Myers Squibb)
- 6.7.4.19 Sprycel (Otsuka/Bristol-Myers Squibb)
- 6.7.4.20 TG 02 (Tragara/S*BIO)
- 6.7.4.21 R763 (Rigel)
- 6.7.5 Heat Shock Protein Modulators
- 6.7.5.1 AUY 922 (Novartis)
- 6.7.5.2 KW 2478 (Kyowa Hakko Kirin)
- 6.7.5.3 NVP BEP800 (Novartis)
- 6.7.6 Apoptosis Inducers: Four Products at Phase II
- 6.7.6.1 GCS 100 (Prospect Therapeutics)
- 6.7.6.2 Amplimexon (AmpliMed )
- 6.7.6.3 Trisenox (Nippon Shinyaku)
- 6.7.6.4 Noscapine (Cougar Biotechnology)
- 6.7.6.5 BMS 833923 (Bristol-Myers Squibb)
- 6.7.6.6 SNS 01-T (Senesco)
- 6.7.7 Other Small-Molecule Myeloma Products
- 6.7.7.1 Products in Phase II
- 6.7.7.2 Amnolake (CytRx)
- 6.7.7.3 Coprexa TM (Attenuon)
- 6.7.7.4 Brostallacin (Cell Therapeutics)
- 6.7.7.5 CYT 997 (YM BioSciences)
- 6.7.7.6 ARRY 520 (Array BioPharma)
- 6.7.7.7 Zinapar (Ziopharm)
- 6.7.7.8 Products in Phase I
- 6.7.7.9 Quadramet (EUSA Pharma)
- 6.7.7.10 LC1 (Leuchemix)
- 6.7.7.11 MLN 4924 (Takeda)
- 6.7.7.12 OPB 31121 (Otsuka)
- 6.7.7.13 Zalypsis (PharmaMar)
- 6.7.7.14 Products in Preclinical Studies
- 6.7.7.15 INNO 206 (CytRx)
- 6.7.7.16 Ostabolin-C (Zelos)
- 6.7.7.17 IRE1-alfa inhibitor (Mannkind)
- 6.7.7.18 HIF Signalling Inhibitors (Elara)
- 6.7.7.19 PS 031291 (Ligand)
- 6.7.7.20 SST 0001 (Sigma-Tau)
- 6.7.7.21 CGEN 928 (Compugen)
- 6.7.7.22 USP7 Inhibitors (Progenra)
- 6.8 Small-Molecule Epigenetic Therapy Pipeline, 2011
- 6.8.1 HDAC Inhibitors
- 6.8.1.1 PXD-101 (Belinostat, TopoTarget/Spectrum Pharmaceuticals)
- 6.8.1.2 LBH589 (Panobinostat, Novartis)
- 6.8.1.3 Entinostat (Syndax Pharmaceuticals)
- 6.8.1.4 4SC-201 (Resminostat, 4SC)
- 6.8.1.5 MGCD-0103 (Mocetinostat, MethylGene)
- 6.8.1.6 SB939 (S*BIO)
- 6.8.1.7 ACY-1215 (Acetylon Pharmaceuticals)
- 6.8.1.8 Valproic Acid
- 6.8.2 DNMT Inhibitors
- 6.8.2.1 SGI-110 (Astex Pharmaceuticals)
- 6.8.2.2 CP-4200 (Clavis Pharma)
7. Qualitative Analysis of the Small-Molecule Cancer Therapies Market, 2011-2021
- 7.1 SWOT Chart for Small-Molecule Cancer Therapies Market 2011-2021
- 7.2 Strengths
- 7.2.1 Cancer Treatment has Proven Commercial Potential
- 7.2.2 High Profile Nature of Cancer
- 7.2.3 Off-Label Prescriptions are Common
- 7.2.4 Strong Drug Development Incentives
- 7.3 Weaknesses
- 7.3.1 Tumours and Multidrug Resistance (MDR)
- 7.3.2 Pricing-Out the Developing World?
- 7.4 Opportunities
- 7.4.1 Cancer is a Key Business Area for the Pharmaceutical Industry
- 7.4.2 Rising Incidence of Cancer
- 7.4.1.1 Aging Populations
- 7.4.1.2 Smoking
- 7.4.1.3 Obesity
- 7.4.1.4 The Developing World
- 7.4.3 Greater Understanding of Cancer Biology Gives Opportunities in the
Cancer Treatment Industry
- 7.4.4 Advanced Diagnostics with Pharmacogenomics: Impact on Cancer
Therapies
- 7.4.5 Live Licensing and In-Life Testing
- 7.4.6 Convenience of Targeted Drugs versus Chemotherapy
- 7.5 Threats
- 7.5.1 Healthcare Spending Restraints Threaten Cancer Drug Revenues
- 7.5.2 The Cost-Effectiveness Debate
- 7.5.3 Governments are a Leading Payer for Drugs
- 7.5.4 Efficacy, Toxicity and Alternative Treatments
- 7.6 Biosimilars and Generics: Opportunity or Threat?
- 7.7 Personalised Medicine and Cancer
- 7.7.1 Biomarkers and Diagnostics
- 7.7.2 Small-Molecule (Metabolic) Biomarkers
- 7.7.3 Cancer Heterogeneity
- 7.7.4 Pharmacogenomics
- 7.7.5 Genome Screening
- 7.7.6 Theranostics
8. Research Interviews
- 8.1 Dr Martin Bonde, CEO, EpiTherapeutics
- 8.1.1 Potential for Histone Methyltransferase Inhibitors
- 8.1.2 Future of Epigenetics Research
- 8.1.3 Histone Methyltransferase Inhibitors on Market within Decade?
- 8.1.4 Challenges in Developing Epigenetic Therapies
- 8.1.5 Benefits of University Spin-Outs
- 8.2 Dr Joanna Horobin, President and CEO, Syndax Pharmaceuticals
- 8.2.1 On Challenges Facing Cancer Therapies
- 8.2.2 On Selective Targeting of Therapies
- 8.2.3 On Drug Resistance and Targeted Therapies
- 8.2.4 On Drug Resistance and Market Opportunity
- 8.2.5 On Entinostat, Lung and Breast Cancer Therapies
9. Conclusions
- 9.1 Small-Molecule Cancer Therapies Market Offers Promise
- 9.2 Leading Products in Small-Molecule Cancer Therapies Market, 2010
- 9.3 The US Will Remain the World's Largest Small-Molecule Cancer Therapies
Market
- 9.4 India and China Will be the Fastest-Growing National Markets
- 9.5 R&D Pipelines for Many Cancer Types Are Strong
- 9.6 Concluding Remarks
List of Tables
- Table 2.1 Leading Causes of Death Worldwide, 2008 & 2015
- Table 2.2 Most Common Cancers by Incidence, 2008
- Table 2.3 Most Common Cancers by Mortality, 2008 & 2015
- Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK, 2009
- Table 2.5 Categories of Anti-Cancer Drug, 2011
- Table 2.6 Common Side Effects of Traditional Antineoplastic Chemotherapy
- Table 2.7 Subcategories of TANs, 2011
- Table 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast,
2010-2015
- Table 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast,
2016-2021
- Table 3.3 Small-Molecule Cancer Market: Top Ten Products - Sales and
Market Shares, 2010, 2015 & 2021
- Table 4.1 Leading Small-Molecule Cancer Therapies: National Market
Forecasts, 2010-2021
- Table 5.1 Glivec/Gleevec Sales for US and RoW, 2009 & 2010
- Table 5.2 Glivec/Gleevec Sales Forecast, 2010-2015
- Table 5.3 Glivec/Gleevec Sales Forecast, 2016-2021
- Table 5.4 Glivec/Gleevec: Sales Drivers and Restraints, 2011-2021
- Table 5.5 Revlimid Sales Forecast, 2010-2015
- Table 5.6 Revlimid Sales Forecast, 2016-2021
- Table 5.7 Revlimid: Sales Drivers and Restraints, 2011-2021
- Table 5.8 Alimta Sales for US and RoW, 2009 & 2010
- Table 5.9 Alimta Sales Forecast, 2010-2015
- Table 5.10 Alimta Sales Forecast, 2016-2021
- Table 5.11 Alimta: Sales Drivers and Restraints, 2011-2021
- Table 5.12 Taxotere: Approved Indications, 2010
- Table 5.13 Taxotere Sales by Region, 2009 & 2010
- Table 5.14 Taxotere Sales Forecast, 2010-2015
- Table 5.15 Taxotere Sales Forecast, 2016-2021
- Table 5.16 Taxotere: Sales Drivers and Restraints, 2011-2021
- Table 5.17 Velcade Sales by Company, 2010
- Table 5.18 Velcade Sales Forecast, 2010-2015
- Table 5.19 Velcade Sales Forecast, 2016-2021
- Table 5.20 Velcade: Sales Drivers and Restraints, 2011-2021
- Table 5.21 Arimidex Sales for US and RoW, 2009 & 2010
- Table 5.22 Arimidex Sales by Region, Q1-Q3 2010
- Table 5.23 Arimidex Sales Forecast, 2010-2015
- Table 5.24 Arimidex Sales Forecast, 2016-2021
- Table 5.25 Arimidex: Sales Drivers and Restraints, 2011-2021
- Table 5.26 Tarceva Sales Forecast, 2010-2015
- Table 5.27 Tarceva Sales Forecast, 2016-2021
- Table 5.28 Tarceva: Sales Drivers and Restraints, 2011-2021
- Table 5.29 Sutent Sales Forecast, 2010-2015
- Table 5.30 Sutent Sales Forecast, 2016-2021
- Table 5.31 Sutent: Sales Drivers and Restraints, 2011-2021
- Table 5.32 Nexavar Sales Forecast, 2010-2015
- Table 5.33 Nexavar Sales Forecast, 2016-2021
- Table 5.34 Nexavar Sales Drivers and Restraints, 2011-2021
- Table 5.35 Sprycel Sales for US and RoW, 2009 & 2010
- Table 5.36 Sprycel Sales Forecast, 2010-2015
- Table 5.37 Sprycel Sales Forecast, 2016-2021
- Table 5.38 Sprycel: Sales Drivers and Restraints, 2011-2021
- Table 6.1 Number of Cancer Drug Pipeline Candidates by Indication, 2009 &
2011
- Table 6.2 Abbreviations Used in Chapter 6
- Table 6.3 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase
III, 2010
- Table 6.4 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase
II, 2010
- Table 6.5 Selected Small-Molecule Breast Cancer Pipeline in Phase II &
III, 2010
- Table 6.6 Selected Small-Molecule Colorectal Cancer Pipeline Candidates in
Phase II & III, 2010
- Table 6.7 Selected Small-Molecule Stomach Cancer Pipeline Candidates in
Phase II & III, 2010
- Table 6.8 Selected Small-Molecule Prostate Cancer Pipeline Candidates in
Phase II & III, 2010
- Table 6.9 Small-Molecule Pipeline Products for Multiple Myeloma, 2011
- Table 6.10 Small-Molecule Multiple Myeloma Pipeline: Proteasome
Inhibitors, 2011
- Table 6.11 Small-Molecule Multiple Myeloma Pipeline: Immunomodulators, 2011
- Table 6.12 Small-Molecule Multiple Myeloma Pipeline: Histone Deacetylase
Inhibitors, 2011
- Table 6.13 Small-Molecule Multiple Myeloma Pipeline: Kinase
Inhibitor/Signal Transduction Blockers, 2011
- Table 6.14 Small-Molecule Multiple Myeloma Pipeline: Heat Shock Protein
Modulators, 2011
- Table 6.15 Small-Molecule Multiple Myeloma Pipeline: Apoptosis Inducers,
2011
- Table 6.16 Other Small-Molecule Myeloma Products: Phase II Pipeline, 2011
- Table 6.17 Other Small-Molecule Myeloma Products: Phase I Pipeline, 2011
- Table 6.18 Other Small-Molecule Myeloma Products: Preclinical Pipeline,
2011
- Table 6.19 Selected Small-Molecule HDAC Inhibitor Pipeline Candidates, 2011
- Table 6.20 Ongoing Clinical Trials for PXD-101 (Belinostat), 2011
- Table 7.1 SWOT Analysis of World Small-Molecule Cancer Drugs Market:
Strengths and Weaknesses, 2011-2021
- Table 7.2 SWOT Analysis of World Small-Molecule Cancer Drugs Market:
Opportunities and Threats, 2011-2021
- Table 9.1 Small-Molecule Cancer Drug Market: Top Ten Products - Sales and
Market Shares, 2010
- Table 9.2 Small-Molecule Cancer Drugs Market by Country, 2010, 2015, 2018
& 2021
List of Figures
- Figure 2.1 Leading Causes of Death Worldwide, 2008 & 2015
- Figure 2.2 Most Common Cancers by Incidence, 2008
- Figure 2.3 Most Common Cancers by Mortality, 2008
- Figure 2.4 Most Common Cancers by Mortality, 2015
- Figure 2.5 Five-Year Survival Rates of Nine Cancers in the UK, 2009
- Figure 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast,
2010-2015
- Figure 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast,
2016-2021
- Figure 3.3 Small-Molecule Cancer Therapies: Sales for Leading Products,
2010
- Figure 3.4 Small-Molecule Cancer Therapies: Sales for Leading Products,
2015
- Figure 3.5 Small-Molecule Cancer Therapies: Sales for Leading Products,
2018
- Figure 3.6 Small-Molecule Cancer Therapies: Sales for Leading Products,
2021
- Figure 4.1 Leading National Small-Molecule Cancer Therapies: Market
Forecasts, 2010-2021
- Figure 4.2 National Small-Molecule Cancer Therapies: Market Forecasts,
Lower Range, 2010-2021
- Figure 4.3 Small-Molecule Cancer Therapies: Sales in Leading National
Markets, 2010
- Figure 4.4 Small-Molecule Cancer Therapies: Sales in Leading National
Markets, 2015
- Figure 4.5 Small-Molecule Cancer Therapies: Sales in Leading National
Markets, 2018
- Figure 4.6 Small-Molecule Cancer Therapies: Sales in Leading National
Markets, 2021
- Figure 5.1 Glivec/Gleevec Sales for US and RoW, 2010
- Figure 5.2 Glivec/Gleevec Sales Forecast, 2010-2021
- Figure 5.3 Revlimid Sales Forecast, 2010-2021
- Figure 5.4 Alimta Sales for US and RoW, 2010
- Figure 5.5 Alimta Sales Forecast, 2010-2021
- Figure 5.6 Taxotere Sales by Region, 2010
- Figure 5.7 Taxotere Sales Forecast, 2010-2021
- Figure 5.8 Velcade Sales by Company, 2010
- Figure 5.9 Velcade Sales Forecast, 2010-2021
- Figure 5.10 Arimidex Sales by Region, Q1-Q3 2010
- Figure 5.11 Arimidex Sales by Region, 2010
- Figure 5.12 Arimidex Sales Forecast, 2010-2021
- Figure 5.13 Tarceva Sales Forecast, 2010-2021
- Figure 5.14 Sutent Sales Forecast, 2010-2021
- Figure 5.15 Nexavar Sales Forecast, 2010-2021
- Figure 5.16 Sprycel Sales for US and RoW, 2010
- Figure 5.17 Sprycel Sales Forecast, 2010-2021
- Figure 6.1 Number of Cancer Drug Pipeline Candidates by Indication, 2009 &
2011
- Figure 9.1 Small-Molecule Cancer Therapies Market: World Sales Forecast,
2010, 2012, 2015, 2018 & 2021
Companies Listed
- 4SC
- AB Science
- Abbott Laboratories
- Abgenix
- Abraxis BioScience
- Acceleron
- Ascenta Therapeutics
- Acetylon
- Actavis
- ACT Biotech
- Active Biotech
- Adeona
- AERES Biomedical
- Aeterna Zentaris
- Agennix
- Alexion
- Alza
- Allos Therapeutics
- American Society of Clinical Oncology (ASCO)
- American Society of Hematology (ASH)
- Amgen
- AmpliMed
- Anthrogenesis
- Apexigen
- Apotex
- APP Pharmaceuticals (part of the Fresenius Kabi Group)
- ARIAD Pharmaceuticals
- Arizona University
- Arno
- Array BioPharma
- Ascenta Therapeutics
- Astellas Pharma
- Astex Therapeutics
- AstraZeneca
- Attenuon
- AVEO Pharmaceuticals
- Barr Laboratories
- Bayer
- Biogen Idec
- BioInvent
- Bionovo
- Biotech Research and Innovation Centre (BRIC), University of Copenhagen
- Biotest
- BioWa
- BiPar Sciences (subsidiary of Sanofi)
- Boehringer Ingelheim
- Bristol-Myers Squibb
- British Biotech
- BTG
- Canadian National Research Council
- Cancer Research Technology
- Cancer Research UK
- Cancer Science Institute of Singapore (CSI Singapore)
- Celanese
- Celgene
- Cell Therapeutics
- Centocor Ortho Biotech
- Cephalon
- Cetus Corporation
- Chiron
- Choongwae
- Cipla
- Clavis Pharma
- Cleveland Clinic
- Columbia University
- Compugen
- Concordia Pharmaceuticals
- Constellation Pharmaceuticals
- Cougar Biotechnology
- Crinos
- CTI Technologies
- CuraGen
- CureVac
- Cyclacel Pharmaceuticals
- CyDex
- Cylene
- Cytogen
- Cytokinetics
- CytRx
- Daiichi Sankyo
- Dako
- Dana Farber Cancer Institute
- Endocyte
- Elan
- EntreMed
- Dendreon
- Dr. Reddy's Laboratories
- Eisai
- Elara Pharmaceuticals
- Eleison Pharmaceuticals
- Eli Lilly
- European Medicines Agency (EMEA/EMA)
- European Molecular Biology Laboratory
- Endocyte
- EntreMed
- EpiTherapeutics
- Epizyme
- EUSA Pharma
- Exelixis
- Facet Biotech
- Food and Drug Administration (US FDA)
- Fresenius Kabi
- Genentech (now part of Roche)
- Generex Biotechnology
- Genmab
- Genta
- Genzyme
- Geron
- GlaxoSmithKline (GSK)
- Gloucester Pharmaceuticals
- GlycoGenesys
- GlycoMimetics
- GPC Biotech
- Greenwich Therapeutics
- GTC Biotherapeutics
- Handok
- Harvard University
- Hospira
- Human Genome Sciences
- IkerChem
- ILEX Oncology
- ImClone Systems (a subsidiary of Eli Lilly)
- Immune System Therapeutics
- ImmunoGen
- Incyte
- Infinity Pharmaceuticals
- Innate Pharma
- Intas Biopharmaceuticals
- Intellikine
- International Cancer Genome Consortium
- International Myeloma Working Group
- Introgen Therapeutics
- Isis Pharmaceuticals
- Italfarmaco
- Janssen-Cilag
- Johnson & Johnson (J&J)
- Kaken
- Karyopharm Therapeutics
- Keryx Biopharmaceuticals
- Keyaku Zentaris
- Kosan Biosciences
- Kyowa Hakko Kirin
- Leuchemix
- Les Laboratoires Servier
- Ligand
- Lipomed
- Lonza
- Mannkind
- Marlborough Research and Development
- Marshall Edwards
- MD Anderson Cancer Center
- MedImmune
- Medivation
- Merck & Co.
- Merck KGaA
- Merck Serono (part of Merck KGaA)
- MethylGene
- Micromet
- Millennium Pharmaceuticals
- MorphoSys
- Mount Sinai Medical Center [US]
- Multiple Myeloma Research Consortium
- Multiple Myeloma Research Foundation
- Mylan
- Natco Pharma
- National Cancer Institute (NCI) [US]
- National Cancer Institute (US)
- National Health Service (NHS) [UK]
- National Institute for Clinical Excellence (NICE) [UK]
- National University Cancer Institute Singapore (NCIS)
- NCIC Clinical Trials Group
- Nektar Therapeutics
- Nereus
- Nerviano Medical Sciences
- Nippon Shinyaku
- Novartis
- Novo Nordisk
- Novogen
- Ohio State University
- OncoGenex Pharmaceuticals
- Oncova
- Ono Pharmaceuticals
- Onyx Pharmaceuticals
- Ortho Biotech
- Otsuka
- Oxford University
- Par Pharmaceutical
- PDL BioPharma
- Pfizer
- Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
- Pharmacia
- Pharmacopeia
- Pharmacyclics
- PharmaMar
- Pharmion
- Pierre Fabre
- Pipex
- Piramal Life Sciences
- PIramed
- PolaRx Biopharmaceuticals
- Poniard Pharmaceuticals
- Proacta
- Progenra
- Prospect Therapeutics
- Protein Design
- Proteolix
- R&R
- Radient Pharmaceuticals
- Regeneron
- Rigel
- Roche
- Rockefeller University
- Roxane Laboratories
- Salk Institute for Biological Studies
- S*BIO
- Sandoz (part of Novartis)
- Sanofi (sanofi-aventis)
- Scancell
- Schering-Plough
- Scripps Institution of Oceanography
- Seattle Genetics
- Semafore
- Senesco
- Shire
- Sigma-Tau
- Signal Pharmaceuticals
- Sirton
- Sloan-Kettering Institute
- Spectrum Pharmaceuticals
- Stada Arzneimittel
- Sun Pharmaceuticals
- Sunesis
- Syndax Pharmaceuticals
- Taiho Pharma
- Takeda
- Tapestry Pharmaceuticals
- TargeGen
- Teva Pharmaceutical Industries
- Texas A&M University
- Threshold Pharmaceuticals
- TMRC
- Toko
- TopoTarget
- Tragara
- Tufts University
- University of Basel PharmaCenter (PharmaCenter Basel)
- University of Cambridge
- University of Kentucky College of Pharmacy
- University of Michigan
- University of San Diego
- US National Comprehensive Cancer Network
- Vernalis
- VioQuest
- Wayne State University
- WILEX
- World Health Organization (WHO)
- Xencor
- XOMA
- XTL Biopharmaceuticals
- Yakult Honsha
- Yeda Research and Development Company
- YM Biosciences
- Zelos
- Zeltia
- Zenyaku Kogyo
- Zeria
- Ziopharm
預計2015年小分子標的癌治療藥的收益將達到273億美元
2012年01月17日
Global Information, Inc.已開始銷售Visiongain所發行的報告書「Small-Molecule Targeted Cancer Therapies: World Market 2011-2021 (全球小分子癌症標靶治療市場：2011-2021)」
Visiongain的本報告書中預測，全球小分子(低分子)標的癌治療的收益，將於2015年時達到273億美元。2010年該治療的收益為203億美元。
2009年全世界被診斷出罹癌的患者數超過1,300萬人，預測在2025年之前，一年間新的癌患者數將變成2,000萬人。
Visiongain的健康護理業界上級分析家Dr Syed Ahmed敘述：「與癌有關的死亡數非常龐大，故需要不只是延長癌患者的生存期間，還要大幅提高生活品質的藥品。
從2011年開始到2021年的製藥市場，包含小分子標的癌治療藥的抗癌藥，將繼續成為重要的部門。」。
標的癌治療是特別抑制有關癌增生和轉移的分子之治療法。
大部分的標的治療乃利用小分子藥或單株抗體(monoclonal antibody)來進行。
有別於抗體治療，小分子標的癌治療藥通過細胞膜到達細胞內的標的。
依據本報告書，小分子標的癌治療市場，受Novartis公司Glivec/Gleevec所代表的許多blockbuster支配。
這些醫藥品有好幾個在近10年內專利期限將到期，預測將為生產學名藥公司帶來市場機會。
儘管如此，由於強力的研究開發管道，對製藥企業來說，小分子癌治療成為具功能性且有前景的領域。
|
